Claudia Hänle
Publications by Year
Research Areas
Estrogen and related hormone effects, Pharmacogenetics and Drug Metabolism, Advanced Breast Cancer Therapies, Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy
Most-Cited Works
- → Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial(2017)1,678 cited
- → Supplementary Table S4 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial(2025)
- → Supplementary Figure S1 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial(2025)
- → Supplementary Table S2 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial(2025)
- → Supplementary Table S1 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial(2025)
- → Durvalumab in Kombination mit Carboplatin/Paclitaxel/Bevacizumab gefolgt von Durvalumab/Bevacizumab/Olaparib Erhaltungstherapie bei Patientinnen mit neu diagnostiziertem fortgeschrittenen Ovarialkarzinom ohne tBRCA1/2-Mutation: Ergebnisse aus der randomisierten, placebokontrollierten Phase-III-DUO-O/AGO-OVAR 23-Studie(2024)
- → Supplementary Table S3 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial(2025)
- → Supplementary Table S5 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial(2025)
- → Supplementary Figure S2 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial(2025)
- → Supplementary Table S6 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial(2025)